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Abstract
Extensive angiogenesis, formation of new capillaries from pre-existing blood vessels, is an important feature of malignant
glioma. Several antiangiogenic drugs targeting vascular endothelial growth factor (VEGF) or its receptors are currently in
clinical trials as therapy for high-grade glioma and bevacizumab was recently approved by the FDA for treatment of
recurrent glioblastoma. However, the modest efficacy of these drugs and emerging problems with anti-VEGF treatment
resistance welcome the development of alternative antiangiogenic therapies. One potential candidate is histidine-rich
glycoprotein (HRG), a plasma protein with antiangiogenic properties that can inhibit endothelial cell adhesion and
migration. We have used the RCAS/TV-A mouse model for gliomas to investigate the effect of HRG on brain tumor
development. Tumors were induced with platelet-derived growth factor-B (PDGF-B), in the presence or absence of HRG. We
found that HRG had little effect on tumor incidence but could significantly inhibit the development of malignant glioma
and completely prevent the occurrence of grade IV tumors (glioblastoma).
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Introduction
Glioma is the most common and lethal type of primary brain
tumor affecting adults. Gliomas are graded between I-IV following
guidelines from the World Health Organization (WHO) [1]. Grade
I-II tumors are considered benign and grade III-IV tumors
malignant. The prognosis of patients diagnosed with malignant
glioma is extremely poor with a median survival of 15 months for
grade IV tumors [2]. Malignant glioma, in particular grade IV
tumors (glioblastoma), often display ample microvascular prolifer-
ations which consists of multilayered, proliferating endothelial cells.
Formation of new capillaries is controlled by proangiogenic and
antiangiogenic factors. One important proangiogenic factor is
VEGF. In high-grade glioma VEGF-A in particular is upregulated
in tumor cells [3,4]. Also the receptors for VEGF-A, VEGFR1 and
VEGFR2 expressed on endothelial cells, are upregulated in glioma
[3,5]. VEGF receptor signaling can promote angiogenesis, blood-
vessel permeability, proliferation and migration of endothelial cells
[6]. There are several anti-VEGF drugs that cause inhibition of
VEGFRsignaling including blockingantibodiesandsmall-molecule
tyrosinekinaseinhibitors[7].AhumanizedantibodyagainstVEGF,
bevacizumab (Avastin), was recently approved by the FDA for
treatment of recurrent glioblastoma [8]. The decision was mainly
based on two phase II trials where Bevacizumab caused a relatively
high radiographic response rate and prolonged progression-free
survival of the patients compared to historical controls [9,10].
However, the effect on overall survival remains to be determined
and in the end tumor progression inevitably resumed. In part, this
may be due to the development of therapy resistance for which
several different mechanisms are being proposed including
increased invasiveness and co-option of cerebral vasculature [11]
and upregulation of other proangiogenic pathways [12].
Histidine-rich glycoprotein (HRG) is a plasma protein of 75 kDa
synthesized by liver parenchymal cells [13]. It is a multidomain
protein displaying two cystatin-like regions at the N-terminus and a
histidine-rich region (HRR) flanked by proline-rich regions (PRR)
closer to the C-terminus [14,15]. HRG can bind a variety of ligands
such as haem, divalent cations, tropomyosin, plasminogen, plasmin,
fibrinogen, thrombospondin, IgG, FccR, C1q, heparin and
heparan sulfate and has been shown to be involved in coagulation,
immune response and angiogenesis [13,16,17,18,19].
HRG may both enhance and inhibit angiogenesis. HRG has
been shown to act as a positive modulator of angiogenesis by
inhibiting the antiangiogenic effect of TSP1 [20]. In contrast,
several studies have suggested an antiangiogenic effect of HRG
mediated by the HRR. HRG could inhibit endothelial cell tube
formation and proliferation, block angiogenesis and induce
apoptosis in endothelial cells [21]. Further, systemic administration
ofHRGwas shown tobe a potentinhibitoroftumorvascularization
in vivo. In mice carrying syngeneic subcutaneous fibrosarcomas
HRG treatment could significantly inhibit tumor growth and
reduce tumor vascularization [22]. Also, when using the minimal
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peptide) to treat subcutaneous human pancreatic adenocarcinomas
in SCID mice tumor vascularization was significantly reduced [23].
The antiangiogenic effect of HRG is suggested to be due to
disruption of focal adhesion function and hence reduced migration
and adhesion of endothelial cells [22,23,24,25].
The limited response of high-grade glioma patients to the current
anti-VEGF drugs in combination with the increased risk of
developing anti-VEGF resistance make additional antiangiogenic
strategies welcome. In the present study we have used the RCAS/
TV-A mouse model of glioma to study the effect of HRG on tumor
formation. RCAS/TV-A is an orthotopic glioma model where
induced tumors show many similarities with human glioma with
regard to histopathology and genetics. The RCAS/TV-A model
utilizes the selective ability of the avian retrovirus RCAS to infect
cellswhichexpressthetv-a receptor.InNtv-amice,tv-a expressionis
driven by the nestin promoter causing infection to be restricted to
neural/glial stem cells [26]. We used the Ntv-a Arf-/- mice and
induced tumors with RCAS-PDGF-B, a combination that mainly
produces high-grade gliomas [27] and analyzed how simultaneous
expression of HRG would affect brain tumor development.
Materials and Methods
Ethics Statement
All animal experiments were done in accordance with the local
animal ethics committee.
Cloning of HRG into RCAS
We received the HRG cDNA (kind gift from Lena Claesson-
Welsh) inserted in the pCEP-Pu2 vector [22]. A fragment
containing the N-terminally His-tagged HRG cDNA in frame
with BM40 signal sequence of pCEP-Pu2 [22,28] was cloned into
RCAS-Y (a derivative of RCASBP(A) [29]) via the pYAP6 adaptor
plasmid. Correct orientation of the insert was confirmed by
restriction enzyme mapping and sequencing with BigDye 3.1
(Applied Biosciences, Carlsbad, CA) according to the manufac-
turer’s protocol and analyzed on an ABI PRISM 3700 DNA
Analyzer (Applied Biosciences).
Transfection of DF-1 Chicken Fibroblasts with RCAS-HRG
The DF-1 chicken fibroblast cell line was cultured as previously
described [30]. The RCAS-HRG construct was transfected into the
DF-1 cells using FuGeneH 6 transfection agent (Roche Diagnos-
tics, Bromma, Sweden) according to the manufacturer’s protocol,
cultured for at least two weeks to ensure efficient virus production
and subsequent infection of the cells before they were used directly
for injection or to harvest conditioned media.
HRG Protein Purification
Conditioned media was collected from DF-1 RCAS-HRG cells
after 3-5 days incubation. His-tagged HRG was purified from the
media using Ni-NTA agarose (Qiagen, Germantown, MD). Eluted
fractions were tested for protein content using the BCA protein
detection kit (Pierce/Thermo Scientific, Rockford, IL). Positive
fractions were pooled and dialyzed against PBS. HRG protein in
PBS buffer was dialyzed to a buffer containing TBS/1 mM ZnCl2,
since Zn
2+ is required for its antiangiogenic activity [24].
Chemotaxis Assay
Human umbilical vein endothelial cells (HUVEC) were cultured
in complete Endothelial Cell Basal Medium MV2 (Promo Cell,
Heidelberg, Germany). The chemotaxis assay was performed using
a modified Boyden chamber with 8 mm micropore polycarbonate
filters (PFB8-50; Neuro Probe Inc., Gaithersburg, MD) coated with
type-1 collagen solution at 100 mg/ml (Vitrogen 100; Collagen
Corp, Palo Alto, CA). HUVEC that had been starved over night in
0.5% FCS/MV2 without additions were trypsinized and resus-
pended at 4610
5 cells/ml in MV2 without additions, 10 mM
ZnCl2, 0.25% BSA and trasylol at 1000 KIE/ml, to stop trypsin
activity. The cell suspension was added in the upper chamber and
growth factor (VEGF-A at 10 ng/ml; Peprotech, Rocky Hill, NJ) in
the lower chamber. HRG was added both in the upper and in the
lower chamber at 100 ng/ml. After 5 h at 37uC cells that had
migrated through the filter were stained with Giemsa and counted.
Data is presented in relation to the number of cells that migrated
through the filter in the absence of VEGF-A or HRG. Statistical
analysis was done with the unpaired t-test using GraphPad Prism
Software 4.0 analysis program.
In vitro Infection of Glial Stem Cells and Proliferation
Assay
Primary glial stem cell cultures were established from neonatal
Ntv-a Arf-/- mice and cultured in N2 medium on polyornithine/
fibronectin coated tissue culture plates with addition of 10 ng/ml
FGF-2, as previously described [30]. Cells were infected for five
days with sterile filtered conditioned N2 media from DF-1 cells
producing RCAS-HRG, RCAS-PDGFB-HA [31] or RCAS-eGFP.
After infection equal number of cells were seeded in 35-mm dishes
for proliferation assay, and on coverslips for immunofluorescence
staining. To determine proliferation cells were counted at day 1, 3
and 7. Statistical analysis was done with the unpaired t-test using
GraphPad Prism Software 4.0 analysis program. Immunofluores-
cence staining was done as described [30] with primary antibodies
rabbit anti-HRG (0119) [22], rabbit anti-eGFP (Abcam, Cam-
bridge, UK) or rabbit anti-HA (Santa Cruz, Santa Cruz, CA).
After incubation with secondary antibody anti-rabbit Alexa555
(Invitrogen, Carlsbad, CA) coverslips were mounted in DAPI
containing ImmuMount (Shandon, Pittsburgh, PA) and pictures
taken using a Zeiss 510 Meta confocal microscope.
Western Blot Analysis
Conditioned media was collected from virus producing cells and
infected glial stem cells and mixed with 4x loading buffer
(Invitrogen) and reducing agent (Invitrogen) before heated at
95uC for 5 min. Western blot analysis was done as described [32].
A primary antibody 0119 [22] raised against the His/Pro-region
was diluted 1:2000 in 1% non-fat dry milk (Bio-Rad, Hercules,
CA) in PBS-T and incubated at 4uC overnight. PDGF-B was
detected using an antibody against HA (1:800, Nordic Biosite,
Ta ¨by, Sweden). Purified recombinant HRG was used as positive
control, medium from DF-1 cells transfected/infected with RCAS-
X (empty RCAS vector) as negative control.
In vivo Glioma Studies
Neonatal mice were intracerebrally injected with 5610
5 RCAS
virus producing DF-1 chicken fibroblasts (RCAS-PDGFB-ires-eGFP
[33] co-injected with either RCAS-HRG or RCAS-X). Mice were
monitored three times per week and killed when ill or at twelve
weeks. The brains were either fixed in 4% formalin for at least
48 h and embedded in paraffin or fixed in 4% PFA for 1 hour at
4uC, immersed in 30% sucrose over night and embedded in OCT
Compound (Sakura Finetech, Torrance, CA). Brain tissue was
sectioned, hematoxylin and eosin stained (H&E) and analyzed in a
blinded procedure by a neuropathologist (TO) for presence and
grade of tumors. Statistical analysis of tumor incidence and grade
distribution with Fisher’s exact test and Kaplan-Meier analysis of
HRG Can Inhibit Glioblastoma
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analysis program.
Immunohistochemical Analysis of Tumors
Immunohistochemical staining was done as described [30].
Before applying the CD31 antibody (goat, 1:200, Santa Cruz)
slides were blocked in 20% normal rabbit serum. Pictures were
taken using a Leica bright field microscope. Immunohistochemical
analysis was performed on 13 out of 13 PDGF-B+HRG (P+H)
tumors and 13 out of 22 PDGF-B+RCAS-X (P+X tumors).
DNA Extraction and Detection of Virally Inserted Genes
DNA was extracted from paraffin embedded tissues, ten 10 mm
tissue sections per sample. After deparaffinisation in xylene and
rehydration in ethanol sections were scraped off the glass and
digested in 50 mM Tris-HCl pH 8.0, 100 mM EDTA pH 8.0,
100 mM NaCl and 1% SDS with addition of 0.25 mg/ml
Proteinase K (Roche) in 55uC for 2 hours. Proteins were removed
using Protein precipitation solution (Promega, Madison, WI) and
DNA precipitated with isopropanol, washed with ethanol and
reconstituted in 10 mM Tris-HCL pH 8.0. For PCR detection
100 ng DNA was used with PuReTaq Ready-To-Go
TM PCR
Beads (GE Healthcare, Uppsala, Sweden) system. Primers used
specific for human PDGF-B were forward primer B1-F (59-
TGCTGCTACCTGCGTCTGGTC) and reverse primer R1 (59-
ATGTTCAGGTCCAACTCGGC) yielding a 158 bp fragment.
The human HRG primers used were forward F2 (59- TTAA-
GAAGGCHAGGCCCAGGTAAA) and reverse R2 (59-TTTA-
GAGGATGTTTGTGGTGCGGC) yielding a 158 bp fragment.
PCR setup used was 95uC for 5 minutes followed by either 35
(PDGFB) or 40 (HRG) cycles of 95uC for 30 s, 55uC for 30 s and
72uC for 1 minute ending at 72uC for 10 minutes. PCR products
were visualized on agarose gels and pictures taken using Gel Foto
System 1000 (Techtum Lab, Umea ˚, Sweden).
RNA Extraction and Detection of RCAS Mediated Gene
Expression
Total RNA was extracted from frozen brain tumor tissue, eight
slides of 20 mm tissue sections per sample using TRIzolH reagent
(Invitrogen). cDNA was made through reverse transcription of
1 mg of total RNA using random primers (S12545, New England
Biolabs, Ipswich, MA) and M-MuLV reverse transcriptase (New
England Biolabs) and subsequently 100 ng of cDNA was used for
PCR detection of PDGF-B and HRG of human origin used in the
RCAS vectors utilizing the PuReTaq Ready-To-Go
TM PCR
Beads (GE Healthcare, Uppsala, Sweden) system. RNA from U-
343MG-a was used as positive control for PDGF-B, DF-1 RCAS-
HRG as positive control for HRG and frozen brain tissue from an
FVB/N mouse as negative control. Primers were the same as for
DNA detection. PCR setup was 95uC for 5 minutes followed by
either 30 (PDGFB) or 40 (HRG) cycles of 95uC for 30 s, 55uC for
30 s and 72uC for 1 minute ending at 72uC for 10 minutes. PCR
products were visualized on agarose gels and pictures taken.
Results
DF-1 Cells Infected with RCAS-HRG Produced Functional
HRG
The HRG gene was cloned into the RCAS-Y vector and the
construct transfected into DF-1 cells for virus production. Western
blot of conditioned media from DF-1 RCAS-HRG cells showed
that HRG protein was produced (Figure 1A). To assure that the
virally produced HRG was functional a chemotaxis assay was
performed. Human umbilical vein endothelial cells (HUVEC)
were stimulated to migrate towards VEGF in a modified Boyden
chamber in the presence or absence of purified HRG (Figure 1B).
HRG on its own did not affect endothelial cell migration. As
expected VEGF could induce a more than two-fold increase in
migration compared to control but when VEGF and HRG were
added together the level of migration was the same as that of
control. Thus, the virally produced HRG was able to significantly
inhibit VEGF induced endothelial cell migration (p=0.0007), in
line with previous data on HRG [22,23,24].
HRG Did Not Affect Primary Glial Cell Proliferation
To analyze if HRG had a direct effect on glial cell proliferation,
primary glial stem cell cultures were set up from neonatal Ntv-a
Arf-/- mouse brains. The cells were infected with RCAS viruses
expressing HRG, PDGFB-HA [31] or eGFP (control) and
subsequently stained for GFP, HRG and HA to determine
infection efficiency (Figure 2A). For proliferation analysis equal
number of cells were seeded on day 0 and cell numbers
determined day 1, 3 and 7. As shown previously for primary glial
cells [27,30] PDGF-B could stimulate glial stem cell proliferation
compared to control infected cells (p=0.0101), while HRG had no
effect on proliferation compared to control cells (p=0.8683)
(Figure 2B).
HRG Could Inhibit PDGF-B Induced Development of
Grade IV Glioma
To analyze the effect of HRG on glioma development neonatal
Ntv-a Arf-/- mice were intracranially injected with equal numbers
Figure 1. RCAS-HRG infected DF-1 cells could produce
functional HRG. (A) Viral produced HRG protein could be detected
by western blot in conditioned media from DF-1 cells infected with
RCAS-HRG but not from RCAS-PDGFB or RCAS-eGFP infected cells.
Purified HRG was used as a positive control (+). (B) Viral produced HRG
could significantly inhibit migration of HUVEC cells towards VEGF. t-test,
** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0008536.g001
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1 RCAS-X (control virus, complete RCAS without inserted
exogenous gene). Mice were monitored for 12 weeks. There was a
small but non-significant effect on tumor incidence (Fischer’s exact
test, p=0.514) by HRG with 42% in PDGF-B+X( P +X) and 34%
in PDGF-B+HRG (P+H) injected mice (Table 1).
To determine HRG expression in tumors we initially tried
immunostainings for HRG protein on tumor sections. Unfortu-
nately, the HRG antibody available to us did not work on
formalin-fixed, paraffin-embedded tissue sections despite extensive
modifications of the protocol. Instead, since RCAS is a retrovirus
we decided to analyze RCAS mediated insertion of PDGF-B and
HRG cDNA in genomic DNA isolated from tumor tissue. DNA
was prepared from formalin-fixed paraffin embedded tissue
sections of two P+X and eleven P+H injected, tumor-bearing
mice. Two of the P+H tumors could not be analyzed since these
tumors were very small (both were grade II) and there was no
tumor tissue remaining. PCR was performed with primers specific
for human PDGF-B and human HRG cDNA. As expected, since
PDGF-B is required for tumor development in this model, we
found human PDGF-B cDNA in all genomic DNA samples
analyzed (Figure 3A). We also found that all P+H tumors were
positive for human HRG cDNA (Figure 3A). To analyze if the
virally transduced PDGF-B and HRG genes were expressed we
isolated RNA from a small set of tumors (two P+X and five P+H)
that had been frozen prior to RNA preparation. Unfortunately,
the fixation of these brains had failed and the histopathology could
not be properly evaluated. Thus, these tumors were not included
in Table 1 or the statistical evaluation of the effect of HRG below.
Expression of human PDGF-B and HRG mRNA was detected
with RT-PCR (Figure 3B). PDGF-B mRNA could be found in all
samples verifying the presence of tumor tissue. HRG mRNA was
clearly detected in one P+H sample (#2566) and weakly in three
samples (#2544, #2545, #2573). One sample (#2630) failed to
show a reliable signal. The fact that HRG expression could not be
consistently detected in one of the P+H tumors and only weakly in
some could be due to that HRG was expressed below the level of
detection, diluted by mRNA from surrounding normal cells, since
P+H tumors generally had both lower tumor cell density and were
smaller in size. There is also the possibility that the tumors were
polyclonal and therefore had expression of HRG in some parts but
not in others, or even that occasional tumors could have been
induced from cells solely infected with RCAS-PDGF-B.
Tumor histopathology was analyzed and tumors were graded
from II-IV. Grade II tumors grew diffusely into the brain
parenchyma and consisted of small, round tumor cells
(Figure 4A–B, upper left panels). Grade III tumors displayed
mitotic figures, cellular and/or nuclear pleomorphism, and
increased microvascular density (Figure 4A–B, upper middle
panels). To be classified as a grade IV tumor, corresponding to
glioblastoma, the addition of pseudopalisading necrosis and/or
microvascular proliferations consisting of multilayered proliferat-
ing endothelial cells had to be present (Figure 4A, right panel). In
control mice (P+X) tumors of all grades were found with the
majority of tumors being high-grade gliomas (grade III–IV,
Figure 4A and 5). There was a clear shift towards lower grade
tumors (grade II) in P+H injected mice (Fischer’s exact test,
p=0.0328) and grade IV tumors were entirely absent in mice that
had received HRG (P+H) (Fischer’s exact test, p=0.019, Figure 4B
and 5).
Reduced Aberrant Tumor Vascularization in HRG Injected
Mice
The tumors were analyzed for expression of various proteins
with immunohistochemical stainings. Tumors of all grades
expressed the glial cell markers OLIG2, SOX2 and PDGFRa
and there was no difference in staining pattern between P+Xa n d
P+H injected mice (data not shown). Immunostainings for Ki67
and quantification of positive cells showed no difference in
tumors of the same grade between the two groups (data not
shown) further supporting the in vitro data that HRG did not seem
to have a direct effect on glial cell proliferation. To determine the
extent of vascularization (presence of endothelial cells) in the
tumors CD31 stainings were performed (Figure 4A–B, lower
Figure 2. HRG had no effect on primary glial cell proliferation.
(A) Primary glial cells were infected with RCAS-eGFP, RCAS-HRG or
RCAS-PDGFB-HA and expression of the viral transduced proteins was
analyzed with immunocytochemistry. The infection efficiency was
similar in all conditions. (B) Proliferation assay on infected cells showed
no effect of HRG compared to control cells on glial cell proliferation at
day 7. Curves show the mean (6SEM) from three independent
experiments for HRG and eGFP, and two independent experiments
for PDGF-B.
doi:10.1371/journal.pone.0008536.g002
Table 1. Tumor incidence in Ntv-a Arf-/- mice injected with
PDGF-B+X( P +X) or PDGF-B+HRG (P+H) RCAS viruses.
RCAS Injected No of tumors Incidence
P+X5 2 2 2 4 2 %
P+H3 8 1 3 3 4 %
doi:10.1371/journal.pone.0008536.t001
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injected mice were similarly positive with increased number of
positive cells with malignancy grade. Normal brain (data not
shown) and low-grade tumors displayed presence of thin and
organized vessels whereas high-grade tumors contained vessels
that often appeared disorganized and multi-layered, suggesting
that an increase in microvascular proliferation is a prerequisite
for malignant glioma to occur.
Figure 3. Presence and expression of viral transduced PDGF-B and HRG in tumors. (A) Insertion of the viral transduced human PDGF-B and
HRG cDNA in genomic DNA prepared from PDGF-B+X( P +X) and PDGF-B+HRG (P+H) induced tumors. The tumor grade is given above each sample.
Genomic DNA from U-706MG-a cells was used as positive control (+), and genomic DNA from an untreated mouse was used as negative control (2).
(B) Expression of human PDGF-B and HRG mRNA in P+X and P+H tumors. RNA extracted from U-343MG and DF-1 RCAS-HRG cells were used as
positive control for PDGF-B and HRG, respectively (+), and RNA from an untreated mouse brain was used as negative control (2).
doi:10.1371/journal.pone.0008536.g003
Figure 4. Tumor histopathology and vessel morphology. (A) Histopathology (H&E) of representative grade II–IV tumors induced with PDGF-
B+X( P +X) and corresponding immunostainings for CD31. Arrows indicate mitoses. (B) Histopathology (H&E) of representative grade II–III PDGF-
B+HRG (P+H) tumors and corresponding CD31 stainings. Bar=100 mm.
doi:10.1371/journal.pone.0008536.g004
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tumor cells can significantly inhibit the development of high-grade
glioma and the mechanism is suggested to be through inhibition of
tumor angiogenesis.
Discussion
To date, there are three antiangiogenic drugs targeting VEGF
signaling (bevacizumab, sunitinib, sorafenib) approved for cancer
therapy [34]. Bevacizumab was the first antiangiogenic drug
approved for use in cancer patients. In combination with
cytotoxic drugs bevacizumab is indicated in treatment of
metastatic colorectal cancer [35], non-small cell lung cancer
[36] and metastatic HER2-negative breast cancer [37], and
recently as single treatment of recurrent glioblastoma [9,10]. The
beneficial effect of combining anti-VEGF treatment with
cytotoxic agents is suggested to be primarily due to improved
drug delivery to the tumor [38]. Large excess of VEGF can
induce vascular permeability and increased interstitial fluid
pressure in the tumor that interferes with efficient drug delivery.
VEGF inhibition is believed to cause normalization of the
vasculature that improves transport across the vessel wall.
However, two recent studies [39,40] report that mice treated
with VEGF-inhibitors display increased tumor invasiveness and
metastasis, although growth of the primary tumor was reduced.
These findings may have important implication for how drugs
targeting VEGF-receptor signaling are used in the clinic. It is
therefore of high priority to find out whether this is a specific
effect of VEGF-inhibitors or a common theme also for other
antiangiogenic strategies.
One hallmark feature of malignant glioma is a marked increase
in microvascular hyperplasias caused by hypoxia-induced VEGF
signaling. These tumor blood vessels are perturbed and leaky
resulting in increased interstitial fluid pressure, peritumoral edema
and incomplete distribution of oxygen and other blood-delivered
factors, including chemotherapeutic drugs, to the tumor [41]. In
addition, it has recently been shown that tumor vessels can
function as a vascular niche for maintainance of glioma cancer
stem cells by producing an as yet unknown factor, and that
reduction of blood vessels caused suppression of tumor growth and
significantly decreased the number of self-renewing tumor cells
[42]. Thus, by suppressing angiogenesis in glioma several tumor
promoting mechanisms will be inhibited.
We have investigated the effect of the antiangiogenic protein
HRG on orthotopic PDGF-B induced glioma development in vivo
using the Ntv-a Arf-/- mice that generate a high proportion of
malignant tumors. Previous studies had shown that it would be
possible to reach therapeutic concentrations of HRG in mice by
systemic administration [22,23]. However, to avoid the potential
problem of not getting HRG through the blood-brain barrier we
decided to express the protein in the tumor cells in this initial
study. We found that HRG could significantly inhibit the
development of malignant tumors and prevent development of
glioblastoma. When analysing the tumor blood vessels we found
that high-grade tumors contained disorganised and often multi-
layered vessels that could not be found in low-grade tumors or
normal brain. This is an important finding, suggesting that
administration of HRG or HRG-derived synthetic peptides could
be potentially valuable in treatment of glioma patients, and
perhaps even more so in combination with already established
treatment modalities. One fatal characteristic of human glioma is
the strong inherent propensity of even benign tumor cells to
malignant progression. Our results imply that HRG therapy may
be effective to prevent tumor progression of low-grade to high-
grade glioma.
Survival is the most used parameter in clinical trials of glioma
therapy and patients with low-grade glioma have significantly
longer survival compared to patients with malignant glioma.
There was no significant effect by HRG on survival of tumor-
bearing mice (data not shown). We believe that the limited time for
the in vivo studies (12 weeks) may not have been sufficient to detect
such an effect since many tumors were found in asymptomatic
mice at the termination of the experiment. The fact that HRG
significantly could inhibit development of malignant glioma
strongly suggests that it also could have a positive effect on
survival in a more long-term study. Also, since HRG was
administered as a separate virus together with the tumor inducing
oncogene double infection of all target cells were required for
efficient HRG expression in the tumors. In some mice the
expression of HRG and PDGF-B could have occurred in separate
cells leading to no or only regional expression of HRG in those
tumors, which may be one reason for why HRG could not be
detected in all P+H tumors.
The current antiangiogenic drugs are promising but not optimal
and problems with VEGF-induced resistance to treatment are
emerging. Therefore, it is vital to find alternative antiangiogenic
treatment strategies not targeting VEGF. The fact that HRG as a
single treatment regimen could inhibit development of malignant
gliomas and completely suppress glioblastoma development is
encouraging and stimulates further studies using HRG alone and
in combination with cytotoxic drugs and receptor tyrosine kinase
(RTK) inhibitors, including VEGF inhibitors, to treat experimen-
tal glioma of all grades.
Figure 5. Distribution of tumor malignancy grades. (A)
Distribution of tumor grades (II–IV) in PDGF-B+X( P +X) and PDGF-
B+HRG (P+H) injected Ntv-a Arf-/- mice. * p,0,05 (B) Distribution of low
grade (II) versus malignant (III+IV) glioma. *p,0,05.
doi:10.1371/journal.pone.0008536.g005
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